Related Experiment Video
Updated: Aug 8, 2026
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
Recombinant interleukin-2 significantly increases the survival of mice with peritonitis, but not acute Staphylococcus
O V Shadrin1, O Y Kaufman, O M Dronova
1Department of Cellular Immunology, All-Union Cancer Research Center, Moscow, Russia.
Abstract:
The effect of recombinant interleukin 2 (rIL-2) on survival of mice with peritonitis and acute Staphylococcus aureus strain 5/2 infection was studied. rIL-2 was ineffective in the case of acute infection when administered simultaneously with LD95 dose of bacteria. The antibiotics (gentamycin or a combination of penicillin and streptomycin) administered in the same fashion cured 100% of animals. rIL-2 proved to be a potent healing agent in the two of three models of S aureus peritonitis. In this case animals received bacteria at days 0 and 2, 4, or 6. rIL-2 was injected at day 0 (group 1), days 0 and 2 (group 2), and days 0, 2, and 4 (group 3). Treatment with rIL-2 was ineffective in group 1; however, in groups 2 and 3 rIL-2 increased the survival up to 90% (in comparison with 30% in the untreated animals of group 2 and 64% in group 3). On the contrary, administration of antibiotics instead of rIL-2 in the group 3 decreased survival to 25%. The perspectives of rIL-2 use in the treatment of bacterial peritonitis, including purous ones, and the cases complicated by immunodepression, are discussed.
Insights
Recombinant interleukin 2 (rIL-2) showed limited efficacy against acute Staphylococcus aureus peritonitis. However, rIL-2 significantly enhanced survival in later-stage infections, suggesting potential for treating complex bacterial peritonitis.
Area of Science:
- Immunology
- Infectious Diseases
- Microbiology
Background:
- Bacterial peritonitis, particularly Staphylococcus aureus infections, poses significant mortality risks.
- The role of immunomodulatory agents like recombinant interleukin 2 (rIL-2) in treating severe bacterial infections requires further investigation.
Purpose of the Study:
- To evaluate the efficacy of rIL-2 in a murine model of Staphylococcus aureus peritonitis.
- To compare rIL-2 treatment with conventional antibiotic therapy in different infection stages.
Main Methods:
- Mice were infected with Staphylococcus aureus and treated with rIL-2 at varying time points (day 0, days 0 and 2, days 0, 2, and 4).
- Survival rates were compared between untreated control groups, rIL-2 treated groups, and antibiotic-treated groups.
- Different infection models were used, including acute and delayed bacterial administration.
Main Results:
- rIL-2 was ineffective when administered simultaneously with a lethal dose of bacteria in acute infection.
- rIL-2 significantly improved survival rates (up to 90%) when administered on days 0 and 2, or days 0, 2, and 4, compared to untreated controls (30-64%).
- Antibiotic treatment, while effective in acute settings (100% survival), decreased survival to 25% when used in a delayed treatment model (group 3).
Conclusions:
- rIL-2 demonstrates therapeutic potential for treating established Staphylococcus aureus peritonitis, especially when administered beyond the initial acute phase.
- The findings suggest a potential role for rIL-2 in managing bacterial peritonitis complicated by immune dysfunction.
- rIL-2's efficacy is dependent on the timing of administration relative to bacterial challenge.
